Group 1 - Sight Sciences, Inc. reported a quarterly loss of $0.23 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.20, and compared to a loss of $0.22 per share a year ago, indicating an earnings surprise of -15% [1] - The company posted revenues of $19.07 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.50%, and showing an increase from $18.75 million in the same quarter last year [2] - Sight Sciences has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates three times during the same period [2] Group 2 - The stock has underperformed, losing about 32.1% since the beginning of the year, while the S&P 500 has declined by only -1.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.23 on revenues of $19.11 million, and for the current fiscal year, it is -$0.91 on revenues of $82.27 million [7] - The Zacks Industry Rank for Medical - Instruments is currently in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Financial Results - Sight Sciences, Inc. announced preliminary unaudited financial results for Q4 and the year ended December 31, 2024[6] - The press release detailing financial results was issued on January 14, 2025[6] Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[5] Regulatory Information - The financial statements and exhibits are not deemed "filed" under the Securities Exchange Act of 1934[7] - The report was signed by Chief Financial Officer Alison Bauerlein[11]

Core Insights - Sight Sciences, Inc. reported financial results for Q4 and full year 2024, with a focus on advancing strategic initiatives for 2025 [1][4][15] Recent Financial Highlights - Q4 2024 revenue was $19.1 million, a 2% increase year-over-year, while full year 2024 revenue was $79.9 million, a 1% decrease compared to 2023 [5][10] - Surgical Glaucoma revenue for Q4 2024 was $18.8 million, up 9% year-over-year, driven by a 7% increase in ordering accounts and a 6% increase in account utilization [5][10] - Dry Eye revenue for Q4 2024 was $0.3 million, down from $1.6 million in the same period last year, attributed to fewer SmartLids sales [5][10] - Gross profit for Q4 2024 was $16.6 million, with a gross margin of 87%, compared to 85% in the prior year [6][11] - Full year 2024 operating expenses were reduced to $118.8 million, a 6% decrease from 2023 [12] Recent Business and Clinical Highlights - The company published a 36-month analysis demonstrating the long-term effectiveness of the OMNI Surgical System for managing glaucoma, showing significant reductions in intraocular pressure [6] - A Budget Impact Analysis indicated that a 20% increase in TearCare market share could yield annual savings of approximately $36.87 per member in a hypothetical health plan with one million covered lives [6] Management Commentary - The CEO emphasized the focus on building commercial momentum in the MIGS market, establishing equitable reimbursement for TearCare, and advancing clinical data to support technology adoption [4] - The company anticipates that the OMNI procedure will remain a leading choice for glaucoma treatment despite market fluctuations [4] 2025 Financial Guidance - Revenue for 2025 is expected to range from $70.0 million to $75.0 million, reflecting a 6% to 12% decline compared to 2024, influenced by new Medicare LCDs affecting MIGS procedures [15] - Adjusted operating expenses for 2025 are projected to be between $105.0 million and $107.0 million, representing a 4% to 6% increase compared to 2024 [16]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Sight Sciences, Inc. due to higher revenues, with a focus on how actual results will compare to estimates impacting stock price [1][2] Earnings Expectations - The earnings report is expected on March 5, 2025, with a consensus estimate of a quarterly loss of $0.20 per share, reflecting a year-over-year change of +9.1% [3] - Revenues are projected to be $18.98 million, which is an increase of 1.2% from the previous year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 4.49% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Sight Sciences is lower than the Zacks Consensus Estimate, leading to an Earnings ESP of -15% [10][11] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with positive readings being more predictive of earnings beats [6][7] - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have shown a nearly 70% success rate in delivering positive surprises [8] Historical Performance - Sight Sciences has beaten consensus EPS estimates three out of the last four quarters, with a recent surprise of +4.35% when it reported a loss of $0.22 against an expected loss of $0.23 [12][13] Conclusion - Despite the potential for an earnings beat, other factors may influence stock movement, and Sight Sciences does not currently appear to be a strong candidate for an earnings beat [14][16]

Core Viewpoint - The OMNI Surgical System demonstrates significant long-term intraocular pressure (IOP) reduction and medication reduction in treating primary open-angle glaucoma, supported by data from a meta-analysis and the IRIS Registry [1][2][4] Group 1: Clinical Effectiveness and Safety - Presentations at the 2025 American Glaucoma Society Annual Meeting will showcase new data on the clinical effectiveness and safety of the OMNI Surgical System across diverse patient populations [1][2] - Data from the IRIS Registry indicates that OMNI, when combined with cataract surgery in Black patients, resulted in significant IOP reductions and decreased medication use over 24 to 36 months [3][4][13] - A systematic review and meta-analysis of 22 studies involving 2,379 eyes concluded that OMNI consistently reduced IOP and medication needs for up to 36 months [6][8] Group 2: Data Sources and Partnerships - The data presented is curated by Verana Health, in partnership with the American Academy of Ophthalmology IRIS Registry, which is one of the largest clinical data registries in medicine [2][4][16] - The IRIS Registry has collected over 851 million patient encounters and 80 million unique de-identified patients from more than 30 electronic health records and 15,000 eye care professionals across the U.S. [4] Group 3: Company Commitment and Future Directions - Sight Sciences emphasizes its commitment to advancing glaucoma care by providing effective treatment options that reduce medication dependence and improve patient quality of life [4][11] - The company aims to transform eye care through innovative interventional technologies, with the OMNI Surgical System being a key product indicated for reducing IOP in adult patients with primary open-angle glaucoma [11][15]

Core Insights - Sight Sciences, Inc. will report its financial results for Q4 and the full year ended December 31, 2024, on March 5, 2025, after market close [1] - A conference call to discuss the results will take place at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day [1] Company Overview - Sight Sciences is an eyecare technology company focused on developing innovative and interventional solutions to improve patient care and transform treatment paradigms [3] - The company offers the OMNI Surgical System, which is an implant-free glaucoma surgery technology aimed at reducing intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION Surgical Instrument is a bladeless device used in ophthalmic surgeries to excise trabecular meshwork [3] - The TearCare System is cleared in the U.S. for localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, addressing the leading cause of dry eye disease [3]

Core Insights - Sight Sciences, Inc. is an eyecare technology company focused on developing innovative interventional technologies to transform care and improve patients' lives [1][3] - The company will present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day on February 27, 2025 [2] Company Overview - Sight Sciences specializes in minimally invasive or non-invasive solutions targeting prevalent eye diseases, aiming to enhance patient care and replace outdated treatment methods [3] - The OMNI® Surgical System is designed for glaucoma surgery, indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma in the U.S. and CE Marked for specific procedures in Europe [3] - The SION® Surgical Instrument is a bladeless device for excising trabecular meshwork in ophthalmic surgeries [3] - The TearCare® System is cleared in the U.S. for localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, addressing the leading cause of dry eye disease [3]

MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day, in New York, NY. Sight Sciences’ management is scheduled to present on Thursday, February 27, 2025, at 7:15 am PT / 10:15 ...

Core Viewpoint - Sight Sciences, Inc. reported preliminary financial highlights for Q4 and full year 2024, indicating a mixed performance with slight revenue growth in Q4 but an overall decline for the year [1][3]. Financial Highlights - Q4 2024 total revenue is expected to be between $18.9 million and $19.1 million, reflecting a 1% increase at the estimated midpoint compared to the same period last year [2]. - Full year 2024 total revenue is projected to be between $79.7 million and $79.9 million, representing a 2% decrease at the estimated midpoint compared to the previous year [3]. - Cash and cash equivalents as of December 31, 2024, were approximately $120 million, up from $118.6 million as of September 30, 2024 [4]. Segment Performance - Surgical Glaucoma revenue for Q4 is expected to be between $18.7 million and $18.8 million, a 9% increase at the estimated midpoint compared to Q4 2023 [5][7]. - Dry Eye revenue for Q4 is expected to be between $0.2 million and $0.3 million, a significant decrease from $1.6 million in the prior year [7]. - Full year Surgical Glaucoma revenue is expected to be between $75.8 million and $75.9 million, a 2% increase at the estimated midpoint compared to the previous year [7]. - Full year Dry Eye revenue is expected to be between $3.9 million and $4.0 million, down from $6.7 million in 2023 [7]. Cash Management - Cash generated in Q4 totaled approximately $1.4 million, a significant improvement compared to cash used of $6.4 million in the same period last year [7]. - Total cash used during the year was approximately $18.1 million, a reduction from $46.9 million in the prior year [7]. - The company aims to achieve cash flow breakeven without raising additional equity capital [7]. Strategic Outlook - The company is focused on effective cash management while investing in long-term value drivers, positioning itself well for 2025 with a strong cash position and differentiated technologies [5]. - The company anticipates continued progress towards establishing equitable reimbursed market access for its TearCare product [5].

Core Viewpoint - Sight Sciences, Inc. reported preliminary financial highlights for Q4 and full year 2024, indicating a mixed performance with slight revenue growth in Q4 but an overall decline for the year [1][3]. Financial Highlights - Q4 2024 total revenue is expected to be between $18.9 million and $19.1 million, reflecting a 1% increase at the estimated midpoint compared to the same period last year [2]. - Full year 2024 total revenue is projected to be between $79.7 million and $79.9 million, representing a 2% decrease at the estimated midpoint compared to the previous year [3]. - Surgical Glaucoma revenue for Q4 2024 is expected to be between $18.7 million and $18.8 million, a 9% increase at the estimated midpoint compared to Q4 2023 [5][7]. - Dry Eye revenue for Q4 2024 is expected to be between $0.2 million and $0.3 million, a significant decrease from $1.6 million in the prior year [7]. - Surgical Glaucoma revenue for the full year 2024 is expected to be between $75.8 million and $75.9 million, a 2% increase at the estimated midpoint compared to the previous year [7]. - Dry Eye revenue for the full year 2024 is expected to be between $3.9 million and $4.0 million, down from $6.7 million in 2023 [7]. - Cash and cash equivalents as of December 31, 2024, were approximately $120 million, up from $118.6 million as of September 30, 2024 [4]. - Cash generated in Q4 totaled approximately $1.4 million, a decrease from $6.4 million cash used in the same period of the prior year [7]. - Total cash used during the year was approximately $18.1 million, significantly down from $46.9 million in the prior year [7]. Strategic Outlook - The company aims to achieve cash flow breakeven without raising additional equity capital, indicating a focus on operational discipline and effective cash management [5][7]. - The company is positioned to execute its long-term vision with a strong cash position and clinically differentiated technologies such as OMNI and TearCare [5].